We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | TG:AMGN | Tradegate | Bond |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.17 | 97.13 | 97.21 | 0 | 22:50:20 |
From May 2019 to May 2024
A federal appeals court ruled Tuesday that Roche Holding AG's (RHHBY) Mircera anemia treatment infringes some patent claims held by Amgen Inc. (AMGN) and it refused to lift a permanent injunction barring Roche from selling Mircera in the United States.
A federal judge in Boston entered the injunction last fall, which barred Roche from competing in the U.S. with Amgen's anemia drugs Aranesp and Epogen.
The U.S. Court of Appeals for the Federal Circuit issued a mixed 81-page ruling Tuesday that sided with each of the companies on some portions of the case.
But despite reversing the trial judge on several issues, the appeals court affirmed that Roche's drug did infringe on some of Amgen's patent claims.
"We do not disturb the court's injunction," the appeals court wrote.
It sent the case back for further proceedings and said the trial court was "free to reconsider the scope of its permanent injunction if it wishes."
The case is Amgen Inc. v. F. Hoffmann-La Roche Ltd., 2009-1020.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
